SCHEMBL24139986

SCHEMBL24139986

CC(C)Oc1ncc(C(C)C)cc1NS(=O)(=O)c1cccc(C(=O)O)c1

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 2/20 0.48
▸ TSHR P16473 1/20 0.48
▸ PTK2B Q14289 1/20 0.48
▸ CCR2 P41597 1/20 0.48
▸ KMT2A Q03164 6/20 0.47
▸ ACLY P53396 2/20 0.47
▸ CASP3 P42574 1/20 0.46
▸ SENP8 Q96LD8 1/20 0.46
▸ SENP7 Q9BQF6 1/20 0.46
▸ SENP6 Q9GZR1 1/20 0.46
▸ AKR1C3 P42330 1/20 0.45
▸ PIK3C2B O00750 1/20 0.43
▸ PIK3C2G O75747 1/20 0.43
▸ ALDH1A1 P00352 1/20 0.43
▸ RAB9A P51151 1/20 0.43
▸ MEN1 O00255 4/20 0.43
▸ MAPT P10636 1/20 0.43
▸ SLC40A1 Q9NP59 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13976075 0.91 ACLY (0.53) KDM4ETSHRPTK2BCCR2KMT2A
SCHEMBL18136822 0.88 CASP3 (0.49) KDM4ETSHRPTK2BCCR2KMT2A
SCHEMBL24139987 0.88 KDM4E (0.48) KDM4ETSHRPTK2BCCR2KMT2A
SCHEMBL16020322 0.86 KDM4E (0.47) KDM4ETSHRPTK2BCCR2KMT2A
SCHEMBL16017555 0.86 KDM4E (0.47) KDM4ETSHRPTK2BCCR2KMT2A
SCHEMBL19558648 0.85 KDM4E (0.52) KDM4ETSHRPTK2BKMT2AACLY
SCHEMBL19558829 0.82 ACLY (0.51) KDM4ETSHRPTK2BCCR2KMT2A
SCHEMBL13975447 0.82 SLC40A1 (0.55) KMT2AACLYALDH1A1MEN1SLC40A1
SCHEMBL13975439 0.76 ACLY (0.55) KDM4ETSHRPTK2BCCR2KMT2A
SCHEMBL24140000 0.76 AKR1C3 (0.56) KDM4ETSHRPTK2BKMT2AAKR1C3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2710018-B1 MACROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS FUNDACION CENTRO NAC DE INVESTIGACIONES ONCOLOGICAS CARLOS III (ES) 2021-12-29 — — EP disclosed
Send feedback